DB05042ExperimentalSmall molecule
SGS518, a novel antagonist for the 5HT6 subtype of the serotonin receptor, is being developed as a treatment for Cognitive Impairment Associated with Schizophrenia (CIAS).
- Mechanism
- Curator reviewed
SGS518 is a selective antagonist of the 5-Hydroxytryptamine-6 (5-HT6) serotonin receptor believed to act by enhancing transmission of chemicals in the brain.
- Primary indication
- Investigated for use/treatment in neurologic disorders and schizophrenia and schizoaffective disorders.Curator reviewed
- Code names
- SGS518
Resolves to
Targets
What you can answer from here — as of April 02, 2025
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with SGS518, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account